Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Palleos Healthcare GmbH
Ottawa Hospital Research Institute
National Institutes of Health Clinical Center (CC)
Vall d'Hebron Institute of Oncology
M.D. Anderson Cancer Center
Albert Einstein College of Medicine
Hoffmann-La Roche
ImmunityBio, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ImmunityBio, Inc.
Samyang Biopharmaceuticals Corporation
Gilead Sciences
University of Nebraska
Leap Therapeutics, Inc.
University of Southern California
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
University of Nebraska
Icahn School of Medicine at Mount Sinai
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Aileron Therapeutics, Inc.
Barbara Ann Karmanos Cancer Institute
Washington University School of Medicine
Dana-Farber Cancer Institute
Karolinska University Hospital
Sun Yat-sen University
Leo W. Jenkins Cancer Center
GlaxoSmithKline
ETOP IBCSG Partners Foundation
The Netherlands Cancer Institute
Prescient Therapeutics, Ltd.
NSABP Foundation Inc
Louisiana State University Health Sciences Center Shreveport
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
AstraZeneca
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
West German Study Group
Centre Jean Perrin
Western Regional Medical Center
Eske Corporation S.A.C
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Emory University
University of Utah
Shanghai Jiao Tong University School of Medicine